New hope for PDL1-negative breast cancer: combo therapy enters trial

NCT ID NCT06954480

Recruiting now Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 20 times

Summary

This study tests whether adding durvalumab to datopotamab deruxtecan works better than datopotamab deruxtecan alone for people with PDL1-negative metastatic triple-negative breast cancer, a type that doesn't respond to standard immunotherapy. About 140 women will be randomly assigned to one of the two treatments. The goal is to see if the combination delays cancer growth or improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Barts Cancer Institute, Centre of Experimental Cancer Medicine
NOT_YET_RECRUITING

London, EC1M 6BQ, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••
Barts Health NHS Trust
RECRUITING

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

TRIPLE NEGATIVE BREAST CANCER